|
|
 |
|
|
 |
Studies & Reports Archive
Personalized Medicine Is Playing a Growing Role in Biopharmaceutical Development Pipelines
16 November, 2010 - A new report from the Tufts Center for the Study of Drug Development finds that biopharmaceutical companies are committed to researching and developing personalized medicines. The data show, for the first time, the extent to which companies are embracing this new research.
Major Advances in Cancer Medicines in 2010
8 November, 2010 - The American Society of Clinical Oncology (ASCO) has issued a new report, Clinical Cancer Advances 2010: ASCO’s Annual Report on Progress Against Cancer, outlining 53 of the most significant advances on the front lines of cancer research over the past year, including 12 major clinical advances in such key areas as personalized medicine and targeted therapies, new treatments and medications for specific diseases, reducing cancer recurrence, quality of life, and more.
Alzheimer’s Burden Will Balloon if New Treatments Are Not Found
15 May, 2010 - A new report from the Alzheimer’s Association examines the future impact of Alzheimer’s disease and the potential impact of new treatments. The study finds that on our current trajectory Alzheimer’s disease in adults over 65 will cost $1 trillion per year by 2050 and a total of $20 trillion in the next 40 years.
Complexity and Execution Burden of Clinical Trials Are Rising
5 May, 2010 - A recent report by Tufts Center for the Study of Drug Development (CSDD) finds that clinical trials are continuing to become more complex and time-consuming. Between 2000-03 and 2004-7, the median number of procedures per clinical trial increased by 49% while the total work burden per protocol grew by 54%.
Recognizing Value in Oncology Innovation
15 March, 2010 - Boston Healthcare Associates released a report which describes how our understanding of the clinical role and value of new cancer treatments evolves over time after they are introduced, and how new treatments with seemingly modest benefits at the time of FDA approval often demonstrate significant clinical advantages for patients over time.
Major Advances in Cancer Medicines in 2009
10 December, 2009 - A new report from the American Society of Clinical Oncology (ASCO) highlighted 51 of the most significant findings of 2009, including 15 major advances that the authors believe “have the potential to lead to a reduction in mortality from cancer”.
Cancer Treatments Have Created Nearly $2 Trillion in Societal Value
1 December, 2009 - A recent working paper from the National Bureau of Economic Research compares the investment in cancer R&D since the beginning of the war on cancer with the value of the increases in survival that resulted between 1988 and 2000 and found that the gains for society and patients have far outweighed the costs, generating 23 million additional life-years and $1.9 trillion in value to society overall.
Statins Help Reduce the Risk of Stroke
1 May, 2009 - A new study in The Lancet Neurology found that in combination with other treatments, cholesterol-lowering drugs, statins, reduce the risk of stroke by 18% and the risk of fatal stroke by 13%. The authors reviewed 24 studies on the effect of statins and other preventative treatments on stroke.
Early HIV Treatment May Improve Survival
30 April, 2009 - A new study published in the New England Journal of Medicine suggests that the initiation of antiretroviral therapy earlier in the course of HIV infection may improve survival.
Impact of the Biopharmaceutical Sector on the U.S. Economy
1 March, 2009 - A new report released by Archstone Consulting and Lawton R. Burns, Ph.D., analyzes the impact that the biopharmaceutical sector has on the U.S. economy. The report provides information at the national, state, and metropolitan statistical area (MSA) levels.
Bone Loss Drug May Help Breast Cancer Patients
12 February, 2009 - A study recently in the New England Journal of Medicine reports that for some women with breast cancer the addition of zoledronic acid to standard treatments can reduce the risk of disease progression by 36%. Zoledronic acid is a drug normally used to prevent complications such as bone pain or fractures in cancer patients with high blood calcium or bone metastasis.
New Cancer Medicines Significantly Advanced Treatment in 2008
22 December, 2008 - A recent report by the American Society of Clinical Oncology (ASCO) identified 12 “major” and 19 “notable” advances in the treatment of cancer in 2008 which “significantly altered the way cancer is understood or had an important impact on patient care.” Among the 12 major advances, 9 related to new medicines, better ways to use existing medicines, or newly discovered benefits or approved medicines.
Cardiovascular Deaths Falling, but Risk Factors on the Rise
15 December, 2008 - According to a 2008 report by the American Heart Association (AHA) death rates for cardiovascular disease fell a dramatic 26% between 1999 and 2005. U.S. deaths from coronary heart disease fell 31% and stroke deaths fell 29% in the same period. Preliminary data showed that these positive trends continued in 2006. According to the lead researcher there would have been an additional 190,000 deaths in 2006 if death rates had remained at 1999 levels. The AHA lists better control of high blood pressure, high cholesterol and tobacco use as factors in the improvement.
Continued Development of Approved Biological Drugs
7 December, 2007 - According to a new study by the Boston Consulting Group, to date, 47 percent of biologics regulated by FDA’s Center for Drug Evaluation and Research have at least one new FDA-approved indication after the initial approval. On average, a biologic that has been on the market for six years is expected to have two additional indications approved over the remainder of it lifetime.
Post-Approval Research on Biotech Medicines Leads to Key Medical Advances
31 October, 2007 - A new paper from the Pharmaceutical Research and Manufacturers of America (PhRMA) about post-approval research on biologics explores how new indications are developed and approved and through several examples illustrates (1) the range of additional indications approved by the FDA and (2) ongoing research into new indications.
Data Exclusivity for New Biological Entities
5 October, 2007 - A new working paper by Duke University economist Dr. Henry Grabowski, “Data Exclusivity for New Biological Entities,” identifies 12.9 to 16.2 years — or about 13 to 16 years — of data exclusivity as necessary to sustain investment in the research and development (R&D) of new biologics in any approach to creating an abbreviated pathway for FOBs.
Breast Cancer Patients Living Longer Thanks to New Medicines
21 September, 2007 - A recent study in the journal Cancer found that survival times for patients with metastatic breast cancer (MBC) improved by 30 percent between the early 1990s and the end of the decade. The researchers link the improvement to new medicines that became available in that period.
Cancer Survival Rates Higher in the U.S. than in Europe
21 September, 2007 - A recent study published in The Lancet Oncology found that survival rates for cancer patients in the United States are higher than in Europe. The study found that for all types of cancers, women in the U.S. had a 63 percent five-year relative survival rate compared to 56 percent in European women. Even more dramatic was that men in the U.S. had a 66 percent relative rate of survival for all types of cancer compared to only 47 percent in Europe.
Data Exclusivity Is Key to Maintaining Continued Innovation in Biologics
27 July, 2007 - A new paper from the Pharmaceutical Research and Manufacturers of America (PhRMA) was released in July about the importance of data exclusivity.
Study Shows Hypertension Treatment and Control Better in the United States than Western Europe
18 July, 2007 - A recent study published in the Archives of Internal Medicine found that lower treatment thresholds and more intensive treatment in the U.S. contributed to better blood pressure control than in western European countries.
Rate of Heart Attack Deaths and Heart Failure Decline
8 June, 2007 - A six-year multinational observational study has provided evidence that death rates and heart failure in hospitalized heart attack patients have sharply declined. Between 1999 and 2005 rates of death and heart failure dropped by nearly half.
Study Suggests Cure for Hepatitis C
8 June, 2007 - Researchers at Virginia Commonwealth University are reporting for the first time that medicines can cure hepatitis C, a viral infection that causes liver inflammation and often leads to cirrhosis and liver cancer.
National Health Spending Slows
31 January, 2006 - An annual study by the Centers for Medicare and Medicaid Services reports that national health spending slowed in 2004, in large part due to a reduced rate of spending on prescription drugs. The annual study found that in 2004 spending for drugs grew by only 8.2 percent, accounting for 10 percent of the total health care spending.
Alliances Increase Success Rate in Clinical Trials
22 June, 2005 - A new study in the Journal of Health Economics found that experience and alliances between smaller research firms and larger pharmaceutical research partners improve the chance of success in clinical trials, particularly for the more complex later stages.
Bio-pharmaceutical R&D estimated at $49.3 billion for 2005
17 March, 2005 - Burrill & Co. and the Pharmaceutical Research and Manufacturers of America (PhRMA) released, for the first time, an estimate of total spending by bio-pharmaceutical companies on research and development.
Use of new drugs reduces mortality
1 November, 2004 - Recent research by Columbia University researcher Frank Lichtenberg found that using newer drugs reduces mortality compared to older drugs.
Alzheimer's Association Report Finds that Investing in Alzheimer's Research Today Could Yield Big Returns
23 June, 2004 - A report issued today by the Alzheimer's Association highlights the critical need to develop new treatments for Alzheimer's disease.
New Web Tool Calculates Productivity Gains of Effective Treatment of Depression
7 June, 2004 - A new internet-based calculator helps employers compute the financial benefits of treating employees with depression.
The Cost of New Drug Discovery and Development
1 June, 2004 - An analysis by Dr. Michael Dickson and Dr. Jean Paul Gagnon looks at the major capital, human, and technological investment required to develop new medicines and explains why the cost and uncertainty of discovery are rising.
Many Insured Patients with High Cholesterol Do Not Receive Medicines They Need to Avoid Increased Risk of Heart Disease - Study
25 May, 2004 - A new study of insured persons with hypercholesterolemia (high cholesterol) finds that over half failed to receive cholesterol-lowering medicines.
|
|
